Skip directly to content

Referencias: Dolor agudo



Referencias en orden alfabético


BALAGUÉ F., MANNION A.F, PELLISÉ F. et al. Non-specif c low back pain. Lancet 2012; 379: 482–91

http://www.sciencedirect.com.proxy1.athensams.net/science/article/pii/S0140673611606107


BHALA, N. et al. (2013) Vascular and upper GI effects of NSAIDs: Meta-analyses of individual participant data from randomized trials by the Coxib and traditional NSAID Trialists’ Collaboration. Lancet. 382. p.769-779 and Supplement.

http://europepmc.org/abstract/med/23726390


CARDENAS-ESTRADA, E. et al. (2009) Efficacy and safety of celecoxib in the treatment of acute pain due to ankle sprain in a Latin American and Middle Eastern population. J Int Med Res. 37. p.1937-1951.

http://imr.sagepub.com.proxy1.athensams.net/content/37/6/1937.short


CHAN, F. K. et al. (2010) Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): A randomised trial. Lancet.[Online] p.1-7. Available from:

http://www.thelancet.com. [Accessed: 21st February 2013].

http://www.sciencedirect.com.proxy1.athensams.net/science/article/pii/S0140673610606733


CHEUNG, R., KRISHNASWAMI, S., KOWALSKI, K. (2007) Analgesic efficacy of celecoxib in postoperative oral surgery pain: a single-dose, two-center, randomized, double-blind, active and placebo-controlled study. Clin Ther. 29. p.2498-2510

http://www.sciencedirect.com.proxy1.athensams.net/science/article/pii/S0149291807003761


CRYER, B. et al. (2013) GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial. Am J Gastroenterol. 108 (3). p.392-400.

http://www.nature.com.proxy1.athensams.net/ajg/journal/v108/n3/abs/ajg2012467a.html


EMERY, P. et al. (1999) Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet. 354: p.2106-2111.

http://www.sciencedirect.com.proxy1.athensams.net/science/article/pii/S0140673699023326


FREYNHAGEN, R. & BARON, R. (2009) The evaluation of neuropathic components in low back pain. Curr Pain Headache Rep. 13 (3). p.185-190.

http://rd.springer.com.proxy1.athensams.net/article/10.1007/s11916-009-0032-y


FREYNHAGEN, R. et al. (2006) painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin.22 (10). p.1911-1920

http://informahealthcare.com.proxy1.athensams.net/doi/abs/10.1185/030079906x132488


HOY D, MARCH L, BROOKS P, et al. The global burden of low back pain: estimates from the Global Burden of Disease 2010 study Ann Rheum Dis 2014;73:968–974

http://ard.bmj.com.proxy1.athensams.net/content/73/6/968.short


JENKINS, K. et al. FDA decision memorandum.

http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm106201.pdf Accessed November 03, 2014.


KOES BW, VAN TULDER MW, THOMAS S. Diagnosis and treatment of low back pain. BMJ 2006;332:1430–4

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1479671/


LEESE, P. T. et al. (2000) Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol. 40 (2). p.124-132.

http://onlinelibrary.wiley.com.proxy1.athensams.net/doi/10.1177/00912700022008766/abstract


MALLEN, SR, ESSEX MN, ZHANG R. Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs. Curr Med Res Opin. 2011;27(7):1359-1366.

http://informahealthcare.com.proxy1.athensams.net/doi/abs/10.1185/03007995.2011.581274


O’DONNELL, J. B. et al. (2009) The effectiveness of a weak opioid medication versus a cyclo-oxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug in treating flare-up of chronic low-back pain: Results from two randomized, double-blind, 6-week studies. J Int Med Res. 37 (6). p.1-14.

http://imr.sagepub.com.proxy1.athensams.net/content/37/6/1789.short


PETRI, M. et al. (2004) Celecoxib effectively treats patients with acute shoulder tendinitis/bursitis. J Rheumatol. 31. p.1614-1620.

http://www.jrheum.org.proxy1.athensams.net/content/31/8/1614.short


ROMANO CL, ROMANO D, BONORO C., et al. Pregabalin, celecoxib, and their combination for treatment of chronic low-back pain. J Orthopaed Traumatol (2009) 10:185–191

http://rd.springer.com.proxy1.athensams.net/article/10.1007/s10195-009-0077-z


SCHROER, W. et al. (2011) Benefits of prolonged postoperative cyclooxygenase-2 inhibitor administration on total knee arthroplasty recovery. J Arthroplasty. 26 (6 Suppl. 1). p.2-7.

http://www.sciencedirect.com.proxy1.athensams.net/science/article/pii/S0883540311001665


SIMON, L. S. et al. (1999) Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA. 282 (20): p.1921-1928.

http://jama.jamanetwork.com.proxy1.athensams.net/article.aspx?articleid=192129


SONI, P. et al. (2009) The hepatic safety and tolerability of the cyclooxygenase-2 selective NSAID celecoxib: pooled analysis of 41 randomized controlled trials. Curr Med Res Opin. 25 (8). p.1841-1851.

http://informahealthcare.com.proxy1.athensams.net/doi/abs/10.1185/03007990903018279


STRAND, V. et al. (2011) Treatment of osteoarthritis with continuous versus intermittent celecoxib. J Rheumatol. 38. p.2625-2634

http://www.jrheum.org.proxy1.athensams.net/content/38/12/2625.short


WHELTON, A. et al. (2006) Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen. Kidney Int. 70 (8). p.1495-1502.

http://www.nature.com.proxy1.athensams.net/ki/journal/v70/n8/abs/5001766a.html


WHITE, P. F. et al. (2007) Effect of short-term postoperative celecoxib administration on patient outcome after outpatient laparoscopic surgery. Can J Anaesth. 54 (5). p.342-348.

http://rd.springer.com.proxy1.athensams.net/article/10.1007/BF03022655


WILNER, K. D. et al. (2002) Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers. J Clin Pharmacol. 42 (9). p.1027-1030.

http://onlinelibrary.wiley.com.proxy1.athensams.net/doi/10.1177/009127000204200910/abstract

 

 

PP-CEL-COL-0028

Este material es de uso exclusivo para el cuerpo médico.
©Pfizer S.A.S Todos los derechos reservados – Prohibida su reproducción total o parcial sin autorización del titular.